Canada, ARIPO and South Korea have granted product patents to Suven Life Sciences Ltd for its new chemical entities (NCEs) used for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2030.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” commented Venkat Jasti, CEO of Suven.
